On Friday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was -5.04% drop from the session before settling in for the closing price of $9.32. A 52-week range for DAWN has been $5.64 – $13.53.
Healthcare Sector giant saw their annual sales slid by -38.09% over the last five years. When this article was written, the company’s average yearly earnings per share was at 1.35%. With a float of $73.65 million, this company’s outstanding shares have now reached $102.68 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Day One Biopharmaceuticals Inc stocks. The insider ownership of Day One Biopharmaceuticals Inc is 28.27%, while institutional ownership is 72.18%. The most recent insider transaction that took place on Nov 17 ’25, was worth 38,503. In this transaction Gen Counsel & Secretary of this company sold 4,319 shares at a rate of $8.91, taking the stock ownership to the 62,626 shares. Before that another transaction happened on Nov 17 ’25, when Company’s COO and CFO sold 4,062 for $8.91, making the entire transaction worth $36,212. This insider now owns 294,715 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.63 earnings per share (EPS) during the time that was less than consensus figure (set at -0.35) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 86.21% during the next five years compared to -38.09% drop over the previous five years of trading.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
You can see what Day One Biopharmaceuticals Inc (DAWN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.49, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
As of the previous 9 days, the stock’s Stochastic %D was 24.33%.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 58.63%, which indicates a significant increase from 30.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.53 in the past 14 days, which was higher than the 0.45 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.65, while its 200-day Moving Average is $7.42. Now, the first resistance to watch is $9.22. This is followed by the second major resistance level at $9.59. The third major resistance level sits at $9.81. If the price goes on to break the first support level at $8.63, it is likely to go to the next support level at $8.41. Should the price break the second support level, the third support level stands at $8.04.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are 102,676K outstanding shares of the company, which has a market capitalization of 908.68 million. As of now, sales total 131,160 K while income totals -95,500 K. Its latest quarter income was 39,800 K while its last quarter net income were -19,730 K.
